Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

NCT02529878 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhejiang Chinese Medical University as lead sponsor.

NCT NCT02529878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
Lead sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2015
Completion date
August 31, 2019
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer